Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)

AIM: To determine the efficacy of 2.0 mg aflibercept in the management of patients with recalcitrant exudative age-related macular degeneration (AMD). METHODS: In this prospective, open-label, single-arm clinical trial, patients were seen monthly and given mandatory 2.0 mg aflibercept at baseline, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wykoff, Charles C, Brown, David M, Maldonado, Maria E, Croft, Daniel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078682/
https://www.ncbi.nlm.nih.gov/pubmed/24518078
http://dx.doi.org/10.1136/bjophthalmol-2013-304736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078682/
https://www.ncbi.nlm.nih.gov/pubmed/24518078
http://dx.doi.org/10.1136/bjophthalmol-2013-304736

Ejemplares similares